The University of Southampton
University of Southampton Institutional Repository

Predictive factors for the benefit of perioperative FOLFOX for resectable liver metastasis in colorectal cancer patients (EORTC Intergroup Trial 40983)

Sorbye, Halfdan, Mauer, Murielle, Gruenberger, Thomas, Glimelius, Bengt, Poston, Graeme J., Schlag, Peter M., Rougier, Philippe, Bechstein, Wolf O., Primrose, John N., Walpole, Euan T, Finch-Jones, Meg, Jaeck, Daniel, Mirza, Darius, Parks, Rowan W., Collette, Laurence, Van Cutsem, Eric, Scheithauer, Werner, Lutz, Manfred P. and Nordlinger, Bernard (2012) Predictive factors for the benefit of perioperative FOLFOX for resectable liver metastasis in colorectal cancer patients (EORTC Intergroup Trial 40983) Annals of Surgery, 255, (3), pp. 534-539. (doi:10.1097/SLA.0b013e3182456aa2). (PMID:22314329).

Record type: Article


Objective: in EORTC study 40983, perioperative FOLFOX increased progression-free survival (PFS) compared with surgery alone for patients with initially 1 to 4 resectable liver metastases from colorectal cancer (CRC). We conducted an exploratory retrospective analysis to identify baseline factors possibly predictive for a benefit of perioperative FOLFOX on PFS.

Methods: the analysis was based on 237 events from 342 eligible patients. Cox proportional hazards regression models with a significance level of 0.1 were used to build up univariate and multivariate models.

Results: after adjustment for identified prognostic factors, moderately (5.1–30 ng/mL) and highly (>30 ng/mL) elevated carcinoembryonic antigen (CEA) serum levels were both predictive for the benefit of perioperative chemotherapy (interaction P = 0.07; hazard ratio [HR] = 0.58 and HR = 0.52 for treatment benefit). For patients with moderately or highly elevated CEA (>5 ng/mL), the 3-year PFS was 35% with perioperative chemotherapy compared to 20% with surgery alone. Performance status (PS) 0 and BMI lower than 30 were also predictive for the benefit of perioperative chemotherapy (interaction P = 0.04 and P = 0.02). However, the number of patients with PS 1 and BMI 30 or higher were limited. The benefit of perioperative therapy was not influenced by the number of metastatic lesions (1 vs 2–4, interaction HR = 0.98).

Conclusions: perioperative FOLFOX seems to benefit in particular patients with resectable liver metastases from CRC when CEA is elevated and when PS is unaffected, regardless of the number of metastatic lesions

Full text not available from this repository.

More information

Published date: March 2012
Organisations: Cancer Sciences


Local EPrints ID: 339801
ISSN: 0003-4932
PURE UUID: 5450daea-41d5-4cdb-aa71-e69cabd0f6cb
ORCID for John N. Primrose: ORCID iD

Catalogue record

Date deposited: 31 May 2012 08:20
Last modified: 18 Jul 2017 05:52

Export record



Author: Halfdan Sorbye
Author: Murielle Mauer
Author: Thomas Gruenberger
Author: Bengt Glimelius
Author: Graeme J. Poston
Author: Peter M. Schlag
Author: Philippe Rougier
Author: Wolf O. Bechstein
Author: Euan T Walpole
Author: Meg Finch-Jones
Author: Daniel Jaeck
Author: Darius Mirza
Author: Rowan W. Parks
Author: Laurence Collette
Author: Eric Van Cutsem
Author: Werner Scheithauer
Author: Manfred P. Lutz
Author: Bernard Nordlinger

University divisions

Download statistics

Downloads from ePrints over the past year. Other digital versions may also be available to download e.g. from the publisher's website.

View more statistics

Atom RSS 1.0 RSS 2.0

Contact ePrints Soton:

ePrints Soton supports OAI 2.0 with a base URL of

This repository has been built using EPrints software, developed at the University of Southampton, but available to everyone to use.

We use cookies to ensure that we give you the best experience on our website. If you continue without changing your settings, we will assume that you are happy to receive cookies on the University of Southampton website.